Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Second Affiliated Hospital of Wenzhou Medical University
With
Wanbangde Pharmaceutical Group Co., LTD
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged between 18 and 80 years (Including 18and 80years, male or female).
One of them:
1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel coronavirus pneumonia (COVID-19).
2. Patients diagnosed clinically as suspected cases.
Ability to communicate well with researchers and sign the informed consent Form (ICF) voluntarily.
You may not be if
ALT≥5 times of ULN, level of total bilirubin≥3 times of ULN, or Cr≥1.5 times of ULN.
Patients with serious severe liver disease.
Excluded who diagnosed as pneumonia patients with novel coronavirus infection of severe type and critical type. 【Diagnostic criteria reference the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5) "】.
Patients with previous history of severe gastrointestinal diseases such as gastric ulcers and bleeding.
Patients with lactose intolerance.
Patients who are allergic to the components of this medicine (Major components: Bromhexine Hydrochloride; excipient: starch, lactose, magnesium stearate).
Positive serum pregnancy test result for women with childbearing potential at screening or lactating women.
Other circumstances that the researcher considers inappropriate to participate in this study.
Clareo Health | Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
